Tag Archives | ADC antibody-drug conjugates

Biotech Stocks Shake Off Fears of Greek Crisis…Update-1… 7/8

Update 7/8/15  12:10p EDT Strange Day with Computer Networks NYSE exchange is down and trading halted- all orders are cancelled. However stocks are trading on other exchanges but at very low volume. United Airlines Grounding Ends after two hour disruption due to a router issue. Apparently no connection but….some other WEB sites are down as well. e.g. […]

Continue Reading 0

Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates

Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its high of $35.50. Update-1 See Chart below of Emerging Orphan drug […]

Continue Reading 0

Rayno Life Science Stocks Move Higher: CLVS, RHHBY-ASCO Preview

Rayno Biopharmaceutical Stocks– ASCO Plays or Not Large Caps Rule Clovis Oncology (CLVS) up 16.7%, 79% YTD to $100 level! Several data CLVS Presentations for ASCO including two oral and six posters for non-small cell lung cancer and ovarian cancer. Also with a valuation of only $3.4B and three platform products in the pipeline including companion […]

Continue Reading 0

Biotech Buzz Is Broken…Update 4/30…#2

Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with profit taking…ADRO, AGIO, JUNO, KITE etc. Large cap Celgene […]

Continue Reading 0

Biotech Bull Market: Trends to Watch in 2015… #3

Biotech Sector Moves Up In Tiny Steps Risk Remains On AACR Next Week Will Move Cancer Stocks Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at the end of Q1. Sentiment remains strong. […]

Continue Reading 0